Effect of BCG on monocyte‐mediated antibody‐dependent cellular cytotoxicity in stage I melanoma

The functional activity of monocytes in human disease and the role of this particular cell type in host defense is a matter of current interest. Among several assays for monocyte function, an antibody‐dependent cellular cytotoxicity microassay is regarded as a convenient test system, in which monocytes of a Ficoll‐Hypaque‐separated mononuclear cell fraction act as effector cells and consequently lyse 51Cr‐labeled, antibody‐coated human erythrocytes. This assay was applied to a total of 35 individuals: 20 patients with Stage I melanoma and 15 healthy control subjects. All melanoma cases were treated by means of excision of the primary lesions and subsequent regional lymphadenectomy. Ten patients were selected at random and received additional adjuvant BCG immunotherapy for periods of 9.4 ± 1.7 months. The mean percentage of 51Cr released in melanoma patients not receiving BCG was significantly lower (P < 0.01%) than that in healthy control subjects. Monocyte numbers, as evaluated by means of nonspecific esterase staining, were not statistically significantly different.

[1]  C. Kjeldsberg,et al.  A qualitative and quantative study of monocytes in patients with malignant solid tumors , 1978 .

[2]  G. Currie,et al.  Monocytes and macrophages in malignant melanoma. II. Lysis of antibody-coated human erythrocytes as an assay of monocyte function. , 1978, British Journal of Cancer.

[3]  M. Territo,et al.  Monocytes and Macrophages: Functions and Diseases , 1978 .

[4]  D. Hedley,et al.  Monocytes and macrophages in malignant melanoma. I. Peripheral blood macrophage precursors. , 1977, British Journal of Cancer.

[5]  P. Perlmann,et al.  Characterization of cytolytic effector cells in peripheral blood of healthy individuals and cancer patients. II. Cytotoxicity to allogeneic or autochthonous tumor cells in tissue culture. , 1977, Journal of immunology.

[6]  R. Snyderman,et al.  Abnormalities of Monocyte Chemotaxis in Patients With Melanoma: Effects of Immunotherapy and Tumor Removal , 1977 .

[7]  R. Blaese,et al.  Monocyte-mediated antibody-dependent cellular cytotoxicity: a clinical test of monocyte function. , 1976, Blood.

[8]  R. Blaese,et al.  The effector cells in human peripheral blood mediating mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity. , 1976, Journal of immunology.

[9]  E. Hersh,et al.  Antibodies to melanoma cell and BCG antigens in sera from tumour-free individuals and from melanoma patients , 1976, Nature.

[10]  H. Oettgen,et al.  Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens , 1976, The Journal of experimental medicine.

[11]  J. Bystryn,et al.  Reproducibility of the immunofluorescent test for antimelanoma antibodies. , 1976, The Journal of investigative dermatology.

[12]  D. Morton,et al.  Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. , 1976, The New England journal of medicine.

[13]  M. Meltzer,et al.  PERITONEAL MACROPHAGES FROM BCG-INFECTED MICE: TUMOR CYTOTOXICITY AND CHEMOTACTIC RESPONSES IN VITRO , 1976 .

[14]  R. Evans.  TUMOR MACROPHAGES IN HOST IMMUNITY TO MALIGNANCIES**This research was supported by grants from the Medical Research Council and the British Cancer Campaign. , 1976 .

[15]  W. Clark,et al.  Regression of pulmonary metastatic disease associated with intralesional bcg therapy of intracutaneous melanoma metastases , 1975 .

[16]  S. Hammarström,et al.  Haemolytic activity of human blood monocytes. Lysis of human erythrocytes treated with anti-A serum. , 1973, Clinical and experimental immunology.

[17]  W. Clark,et al.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.

[18]  C. Southam,et al.  Abnormal cellular response to skin abrasion in cancer patients , 1963 .